MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 205829 | Name: CC-115
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. CC-115 binds to and inhibits the activity of DNA-PK and both raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2), which may lead to a reduction in cellular proliferation of cancer cells expressing DNA-PK and TOR. DNA-PK, a serine/threonine kinase and a member of the PI3K-related kinase subfamily of protein kinases, is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks via the DNA nonhomologous end joining (NHEJ) pathway.

Chemical Structure

CC-115
CC-115
CAS#1228013-15-7 (free base)

Theoretical Analysis

MedKoo Cat#: 205829

Name: CC-115

CAS#: 1228013-15-7 (free base)

Chemical Formula: C16H16N8O

Exact Mass: 336.1447

Molecular Weight: 336.14

Elemental Analysis: C, 57.13; H, 4.79; N, 33.31; O, 4.76

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 1,950.00 Ready to ship
1g USD 3,250.00 2 weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1228013-15-7 (free base) 1300118-55-1 (HCl)
Synonym
CC115 ; CC-115; CC 115.
IUPAC/Chemical Name
1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
InChi Key
GMYLVKUGJMYTFB-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H16N8O/c1-3-24-13(25)7-18-15-16(24)22-12(6-17-15)10-4-5-11(21-9(10)2)14-19-8-20-23-14/h4-6,8H,3,7H2,1-2H3,(H,17,18)(H,19,20,23)
SMILES Code
O=C1CNC2=NC=C(C3=CC=C(C4=NC=NN4)N=C3C)N=C2N1CC
Appearance
Red Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# CAS#1228013-15-7 (CC-115 free base); CAS#1300118-55-1 (CC-115 .xHCl salt)      
Biological target:
CC-115 is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively, that blocks both mTORC1 and mTORC2 signaling.
In vitro activity:
To evaluate the impact of CC-115 inhibition of mTOR kinase and DNA-PK, CC-115 was tested in vitro across a panel of 123 cancer cell lines composed of 40 lymphoma and leukemia, 22 breast cancer, 11 hepatocellular carcinoma, 11 head and neck cancer, and 39 lung cancer cell lines. CC-115 has potent growth inhibitory activity against the majority of the cancer cell lines with GI50 values ranging from 0.015 μM to 1.77 μM (Figure2A2A and Supplementary Table 2). While selective inhibitors of mTOR kinase have been reported to primarily result in cell cycle arrest without significant induction of apoptosis in solid tumor lines, in a subset of both hematological and solid tumor cell lines, CC-115 induced strong apoptosis. CC-115 also inhibited NHEJ activity in a concentrationdependent manner. Partial inhibition was observed with 0.5 μM CC-115 treatment (lane 3) and 5 μM CC-115 achieved complete inhibition (lane 4). Therefore, CC-115 prevents NHEJ by blocking autophosphorylation of DNA-PKcs and dissociation of DNA-PKcs and the ligase IV/XLF/XRCC4 complex from the dsDNA end. This study suggests the use of ATM deficiency as a patient selection strategy for CC-115 as a single agent. Reference: Oncotarget. 2017 Sep 26; 8(43): 74688–74702. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650372/
In vivo activity:
The in vivo activity of CC-115 was tested. As described, 786-O cells were s.c. injected into the flanks of the nude mice. Xenografts were established within three weeks (tumor volumes close to 100 mm3, labeled as “Day-0”). The tumor-bearing mice were randomly assigned into three groups, receiving CC-115 or vehicle control. Results demonstrated that oral administration of CC-115, at 2 mg/kg or 5 mg/kg, significantly inhibited subcutaneous 786-O xenograft growth in nude mice (Figure 5A). The estimated daily 786-O tumor growth, calculated by (tumor volume at Day-30 subtracting tumor volume at Day-30)/30, was dramatically inhibited in CC-115treated mice (Figure 5B). Tumors of all three groups were isolated at Day-30 and weighted (Figure 5C). Tumors with CC-115 treatment were much lighter than the vehicle-treated tumors (Figure 5C). The mouse body weights were not significantly different between the three groups (Figure 5D). Collectively, oral administration of CC-115 inhibited subcutaneous 786-O xenograft growth in mice. Reference: Aging (Albany NY). 2020 Oct 31; 12(20): 20445–20456. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655216/
Solvent mg/mL mM
Solubility
DMSO 43.5 129.41
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 336.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Tsuji T, Sapinoso LM, Tran T, Gaffney B, Wong L, Sankar S, Raymon HK, Mortensen DS, Xu S. CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro. Oncotarget. 2017 Aug 18;8(43):74688-74702. doi: 10.18632/oncotarget.20342. PMID: 29088817; PMCID: PMC5650372. 2. Zheng B, Sun X, Chen XF, Chen Z, Zhu WL, Zhu H, Gu DH. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging (Albany NY). 2020 Oct 27;12(20):20445-20456. doi: 10.18632/aging.103847. Epub 2020 Oct 27. PMID: 33109772; PMCID: PMC7655216.
In vitro protocol:
1. Tsuji T, Sapinoso LM, Tran T, Gaffney B, Wong L, Sankar S, Raymon HK, Mortensen DS, Xu S. CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro. Oncotarget. 2017 Aug 18;8(43):74688-74702. doi: 10.18632/oncotarget.20342. PMID: 29088817; PMCID: PMC5650372. 2. Zheng B, Sun X, Chen XF, Chen Z, Zhu WL, Zhu H, Gu DH. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging (Albany NY). 2020 Oct 27;12(20):20445-20456. doi: 10.18632/aging.103847. Epub 2020 Oct 27. PMID: 33109772; PMCID: PMC7655216.
In vivo protocol:
1. Zheng B, Sun X, Chen XF, Chen Z, Zhu WL, Zhu H, Gu DH. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging (Albany NY). 2020 Oct 27;12(20):20445-20456. doi: 10.18632/aging.103847. Epub 2020 Oct 27. PMID: 33109772; PMCID: PMC7655216.
1: Chen F, Zhao H, Li C, Li P, Zhang Q. An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth. Cell Death Discov. 2022 Jun 18;8(1):293. doi: 10.1038/s41420-022-01082-6. PMID: 35717530; PMCID: PMC9206683. 2: Tsuji T, Sapinoso LM, Tran T, Gaffney B, Wong L, Sankar S, Raymon HK, Mortensen DS, Xu S. CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro. Oncotarget. 2017 Aug 18;8(43):74688-74702. doi: 10.18632/oncotarget.20342. PMID: 29088817; PMCID: PMC5650372. 3: Castellano GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, Malhotra J, Minko T, Pine SR. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022 Sep 6;21(9):1381-1392. doi: 10.1158/1535-7163.MCT-22-0053. PMID: 35732569; PMCID: PMC9452486. 4: Beebe J, Zhang JT. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance. J Pharmacol Exp Ther. 2019 Nov;371(2):320-326. doi: 10.1124/jpet.119.258392. Epub 2019 Aug 27. PMID: 31455631. 5: Zheng B, Sun X, Chen XF, Chen Z, Zhu WL, Zhu H, Gu DH. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging (Albany NY). 2020 Oct 27;12(20):20445-20456. doi: 10.18632/aging.103847. Epub 2020 Oct 27. PMID: 33109772; PMCID: PMC7655216. 6: Bürkel F, Jost T, Hecht M, Heinzerling L, Fietkau R, Distel L. Dual mTOR/DNA- PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential. Int J Mol Sci. 2020 Dec 7;21(23):9321. doi: 10.3390/ijms21239321. PMID: 33297429; PMCID: PMC7730287. 7: Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G Jr, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. First- In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 2019 Dec 13;11:10463-10476. doi: 10.2147/CMAR.S208720. PMID: 31853198; PMCID: PMC6916675. 8: Mortensen DS, Perrin-Ninkovic SM, Shevlin G, Elsner J, Zhao J, Whitefield B, Tehrani L, Sapienza J, Riggs JR, Parnes JS, Papa P, Packard G, Lee BG, Harris R, Correa M, Bahmanyar S, Richardson SJ, Peng SX, Leisten J, Khambatta G, Hickman M, Gamez JC, Bisonette RR, Apuy J, Cathers BE, Canan SS, Moghaddam MF, Raymon HK, Worland P, Narla RK, Fultz KE, Sankar S. Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. J Med Chem. 2015 Jul 23;58(14):5599-608. doi: 10.1021/acs.jmedchem.5b00627. Epub 2015 Jul 8. PMID: 26102506. 9: Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27. PMID: 27235137. 10: Glinkina K, Groenewoud A, Teunisse AFAS, Snaar-Jagalska BE, Jochemsen AG. Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen. Cancers (Basel). 2022 Jun 29;14(13):3186. doi: 10.3390/cancers14133186. PMID: 35804957; PMCID: PMC9264875. 11: Leeksma AC, Derks IAM, Garrick B, Jongejan A, Colombo M, Bloedjes T, Trowe T, Leisten JC, Howarth M, Malek M, Mortensen DS, Blease K, Groza MC, Narla RK, Loos R, Kersten MJ, Moerland PD, Guikema JEJ, Kater AP, Eldering E, Filvaroff EH. SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma. Mol Oncol. 2023 Feb;17(2):284-297. doi: 10.1002/1878-0261.13343. Epub 2022 Dec 16. PMID: 36400430; PMCID: PMC9892823. 12: Liang J, Zhao Y, Xi Y, Xiang C, Yong C, Huo J, Zou H, Hou Y, Pan Y, Wu M, Xie Q, Lin Q. Association between Depression, Anxiety Symptoms and Gut Microbiota in Chinese Elderly with Functional Constipation. Nutrients. 2022 Nov 25;14(23):5013. doi: 10.3390/nu14235013. PMID: 36501044; PMCID: PMC9740187. 13: Shikany JM, Demmer RT, Johnson AJ, Fino NF, Meyer K, Ensrud KE, Lane NE, Orwoll ES, Kado DM, Zmuda JM, Langsetmo L; Osteoporotic Fractures in Men (MrOS) Research Group. Association of dietary patterns with the gut microbiota in older, community-dwelling men. Am J Clin Nutr. 2019 Oct 1;110(4):1003-1014. doi: 10.1093/ajcn/nqz174. PMID: 31504105; PMCID: PMC6766444. 14: Raman M, Middleton RJ, Kalra PA, Green D. Outcomes in dialysis versus conservative care for older patients: A prospective cohort analysis of stage 5 Chronic Kidney Disease. PLoS One. 2018 Oct 26;13(10):e0206469. doi: 10.1371/journal.pone.0206469. PMID: 30365538; PMCID: PMC6203391. 15: Langsetmo L, Johnson A, Demmer RT, Fino N, Orwoll ES, Ensrud KE, Hoffman AR, Cauley JA, Shmagel A, Meyer K, Shikany JM. The Association between Objectively Measured Physical Activity and the Gut Microbiome among Older Community Dwelling Men. J Nutr Health Aging. 2019;23(6):538-546. doi: 10.1007/s12603-019-1194-x. PMID: 31233075; PMCID: PMC6618308. 16: Faulhaber EM, Jost T, Symank J, Scheper J, Bürkel F, Fietkau R, Hecht M, Distel LV. Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells. Genes (Basel). 2021 Jun 17;12(6):925. doi: 10.3390/genes12060925. PMID: 34204447; PMCID: PMC8235750. 17: Adhikari B, Hernandez-Patlan D, Solis-Cruz B, Kwon YM, Arreguin MA, Latorre JD, Hernandez-Velasco X, Hargis BM, Tellez-Isaias G. Evaluation of the Antimicrobial and Anti-inflammatory Properties of Bacillus-DFM (Norum™) in Broiler Chickens Infected With Salmonella Enteritidis. Front Vet Sci. 2019 Aug 27;6:282. doi: 10.3389/fvets.2019.00282. PMID: 31508436; PMCID: PMC6718558. 18: Warheit DB, Hartsky MA, McHugh TA, Kellar KA. Biopersistence of inhaled organic and inorganic fibers in the lungs of rats. Environ Health Perspect. 1994 Oct;102 Suppl 5(Suppl 5):151-7. doi: 10.1289/ehp.94102s5151. PMID: 7882921; PMCID: PMC1567301. 19: Chen X, Kong Q, Zhao X, Zhao C, Hao P, Irshad I, Lei H, Kulyar MF, Bhutta ZA, Ashfaq H, Sha Q, Li K, Wu Y. Sodium acetate/sodium butyrate alleviates lipopolysaccharide-induced diarrhea in mice via regulating the gut microbiota, inflammatory cytokines, antioxidant levels, and NLRP3/Caspase-1 signaling. Front Microbiol. 2022 Oct 28;13:1036042. doi: 10.3389/fmicb.2022.1036042. PMID: 36386709; PMCID: PMC9664939. 20: Dobler C, Jost T, Hecht M, Fietkau R, Distel L. Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells. Cells. 2020 Sep 1;9(9):2012. doi: 10.3390/cells9092012. PMID: 32883016; PMCID: PMC7563880.